Novartis enters IMPRESS
Novartis joins the IMPRESS oncology study with six of its cancer medicines to treat up to one hundred patients.
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 277 entries.
Novartis joins the IMPRESS oncology study with six of its cancer medicines to treat up to one hundred patients.
Five new partners have joined CONNECT.
Eva S. Dugstad is our new research and industry facilitator aka competence broker for Oslo-based companies.
Office spaces have transformed into laboratories in Oslo Cancer Cluster Incubator.
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.